Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab.
HER2 c-erbB2
HER2/neu
T-DM1
advanced breast cancer
chemotherapy
metastatic
pertuzumab
trastuzumab
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Oct 2020
17 Oct 2020
Historique:
received:
21
08
2020
revised:
02
10
2020
accepted:
07
10
2020
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
22
10
2020
Statut:
epublish
Résumé
The approval of trastuzumab emtansine (T-DM1) was conducted without pertuzumab as previous therapy. Efficacy data on T-DM1 following pertuzumab treatment are therefore limited. This study explores this issue in a real-world setting. Within the prospective PRAEGNANT (Prospective Academic Translational Research Network for the Optimization of the Oncological Health Care Quality in the Advanced Setting) metastatic breast cancer registry (NCT02338167), patients in all therapy lines receiving any kind of treatment were eligible for inclusion. This report describes patient characteristics and progression-free survival (PFS) in human epidermal growth factor receptor 2 (HER2)-positive patients receiving T-DM1 after pertuzumab treatment. Seventy-six patients were identified, 39 of whom received T-DM1 as second-line therapy, 25 as third-line, and 12 as fourth-line therapy or higher. Pertuzumab was mostly administered as a first-line treatment (
Identifiants
pubmed: 33080911
pii: cancers12103021
doi: 10.3390/cancers12103021
pmc: PMC7603111
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet Oncol. 2018 Jan;19(1):115-126
pubmed: 29175149
Breast Cancer Res Treat. 2016 Jul;158(1):59-65
pubmed: 27283834
Lancet. 2017 Jun 17;389(10087):2415-2429
pubmed: 27939064
Lancet Oncol. 2012 Jan;13(1):25-32
pubmed: 22153890
Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1090-1099
pubmed: 31656319
Value Health. 2017 Jul - Aug;20(7):866-875
pubmed: 28712615
J Clin Oncol. 2020 Sep 20;38(27):3138-3149
pubmed: 32678716
Oncotarget. 2017 May 25;8(34):56921-56931
pubmed: 28915642
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
Geburtshilfe Frauenheilkd. 2018 Mar;78(3):237-245
pubmed: 29576629
J Clin Oncol. 2016 Oct 10;34(29):3511-3517
pubmed: 27298406
J Clin Oncol. 2019 Sep 1;37(25):2206-2216
pubmed: 31157583
Geburtshilfe Frauenheilkd. 2017 Jun;77(6):633-644
pubmed: 28769126
Breast. 2018 Feb;37:42-51
pubmed: 29100043
Breast. 2018 Feb;37:154-160
pubmed: 29237546
Cancers (Basel). 2018 Dec 21;11(1):
pubmed: 30577662
J Clin Oncol. 2017 Jan 10;35(2):141-148
pubmed: 28056202
Drugs. 2017 Oct;77(15):1695-1704
pubmed: 28884417
Ann Oncol. 2013 Sep;24(9):2278-84
pubmed: 23704196
Eur J Cancer. 2018 Jan;89:27-35
pubmed: 29223479
J Clin Oncol. 2020 Aug 10;38(23):2610-2619
pubmed: 32468955
Ann Oncol. 2017 Apr 1;28(4):855-861
pubmed: 28119295
Lancet Oncol. 2013 May;14(6):461-71
pubmed: 23602601
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Lancet Oncol. 2016 Jun;17(6):791-800
pubmed: 27179402
Breast Cancer Res Treat. 2008 Dec;112(3):533-43
pubmed: 18188694
N Engl J Med. 2006 Dec 28;355(26):2733-43
pubmed: 17192538
Geburtshilfe Frauenheilkd. 2015 Jan;75(1):41-50
pubmed: 25684786
Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1079-1089
pubmed: 31656318
Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259
pubmed: 29576630
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
Lancet Oncol. 2017 Jun;18(6):732-742
pubmed: 28526536
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Geburtshilfe Frauenheilkd. 2017 Dec;77(12):1281-1290
pubmed: 29269955
N Engl J Med. 2020 Feb 13;382(7):597-609
pubmed: 31825569
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153